The Prognostic Value of the Prognostic Nutritional Index in Operable High-Grade Glioma Patients and the Establishment of a Nomogram

Qian He¹, Wei Zhao² and Qinglan Ren³*

¹ Department of Oncology, Affiliated Dongguan People’s Hospital, Southern Medical University, Dongguan, China,
² Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China,
³ Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Background: Studies confirmed the predictive value of the prognostic nutrition index (PNI) in many malignant tumors. However, it did not reach a consensus in glioma. Therefore, this study investigated the prognostic value of preoperative PNI in operable high-grade glioma and established a nomogram.

Methods: Clinical data of high-grade glioma patients were retrospectively analyzed. The primary endpoint was overall survival (OS). Survival analysis was conducted by the Kaplan–Meier method, log-rank test, and Cox regression analysis. A nomogram was established. The prediction effect of the nomogram covering PNI was verified by area under the curve (AUC).

Results: A total of 91 operable high-grade glioma patients were included. Kaplan–Meier analysis showed that among grade IV gliomas (n = 55), patients with higher PNI (>44) showed a trend of OS benefit (p = 0.138). In grade III glioma (n = 36), patients with higher PNI (>47) had longer OS (p = 0.023). However, the intersecting Kaplan–Meier curve suggested that there may be some confounding factors. Cox regression analysis showed that higher PNI was an independent prognostic factor for grade IV glioma (HR = 0.388, p = 0.040). In grade III glioma, there was no statistically relationship between PNI levels and prognosis. When evaluating the prognostic ability of PNI alone by ROC, the AUC in grade III and IV gliomas was low, indicating that PNI alone had poor predictive power for OS. Interestingly, we found that the nomogram including preoperative PNI, age, extent of resection, number of gliomas, and MGMT methylation status could predict the prognosis of patients with grade IV glioma well.

Conclusion: The PNI level before surgery was an independent prognostic factor for patients with grade IV glioma. The nomogram covering PNI in patients with grade IV glioma also proved the value of PNI. However, the value of PNI in grade III glioma needs to be further evaluated. More prospective studies are needed to verify this conclusion.

Keywords: prognostic nutritional index, high-grade glioma, prognostic, overall survival, nomogram
INTRODUCTION

The overall prognosis of patients with high-grade glioma is poor, and the survival of patients varied greatly, and their 5-year survival rate fluctuates between 5.5% and 75.2% (1). Therefore, it is very important to accurately predict the prognosis of patients. Research showed that the prognosis of patients with high-grade glioma was related to factors such as patient age, tumor characteristics, and treatment methods (1). Nevertheless, the accuracy in predicting the prognosis of high-grade gliomas is still limited. It is necessary to find more prognostic factors to comprehensively evaluate the prognosis of patients with high-grade glioma.

Studies showed that the nutritional status and inflammation of patients may affect the antitumor effect (2–5). The prognostic nutritional index (PNI) is based on the serum albumin count and lymphocyte count and is a comprehensive index for evaluating the nutritional status and inflammatory state of the body. Its calculation formula is serum albumin concentration (g/L) + 5× total lymphocyte count (10^3) / L). More and more studies found that higher PNI can be used for independent factors for better prognosis of various malignant tumors, such as lung cancer (6), esophageal cancer (7), breast cancer (8), nasopharyngeal cancer (9), colorectal cancer (10), gastric cancer (11), and biliary tract cancer (12). However, there is no consensus on the role of PNI in glioma (13). Therefore, this study intended to explore the prognostic value of PNI in patients with operable high-grade glioma.

METHODS

Patients

The clinical data of operable high-grade glioma patients from December 2013 to December 2019 in the First Affiliated Hospital of Chongqing Medical University were analyzed retrospectively. The inclusion criteria include the following (1): patients underwent tumor resection (2); patients with high-grade glioma diagnosed according to the 2016 WHO classification and global standard classification (3); patients who completed the "STU P" radiotherapy and chemotherapy protocol (4); regular follow-up; and (5) blood routine and serum albumin examination within 1 week before operation. The exclusion criteria include the following (1): incomplete clinical data (2); receiving other treatments before tumor resection; and (3) having infection or inflammatory disease during the last month.

Data Collection and Hematological Examination

Clinical data of patients were collected including age, gender, tumor grade, histological type, tumor site, tumor number, and extent of resection. The extent of surgical resection was determined according to the preoperative and postoperative MRI and the surgeon’s intraoperative judgment. Postoperative MRI was obtained within 24–72 h after surgery. We used Carestream Vue PACS software to calculate the percentage of resection based on the preoperative MRI and postoperative MRI within 24–72 h and marked the tumor extent according to T1-enhanced sequence images. The percentage of tumor resection = (preoperative tumor volume - residual tumor volume) / preoperative tumor volume * 100%. No tumor remaining was considered as gross total resection (GTR), tumor resection extent > 90% was considered as near total resection (NTR), tumor resection extent between 80% and 90% was considered as subtotal resection (STR), and tumor resection extent < 80% was considered as partial resection (PR). Blood routine and serum albumin results before surgery were collected. The cutoff value of the optimal PNI was obtained by X-Tile software.

Follow-Up

The primary endpoint of the study was OS. OS was defined as the time from the day of surgery to the death of the patient or the final follow-up. There were 91 patients who met the inclusion and exclusion criteria and were successfully followed up. The follow-up ended on September 12, 2020.

Statistical Analysis

We used the independent sample T test or Mann–Whitney U test to compare continuous variables, and the chi-square test or Fisher’s exact probability test to compare categorical variables. The Kaplan–Meier method, log-rank method, and Cox regression model were used for survival analysis. Survival was analyzed by calculating the hazard ratio (HR) and 95% confidence interval (CI). The prognostic ability of PNI was evaluated by the area under the curve (AUC) through the ROC curve. A nomogram covering the PNI was built, and the C index was calculated. The predictive effect of the nomogram was verified by the calibration curve through bootstrap sampling 1,000 times. The predictive ability of the nomogram covering PNI and the predictive model without PNI was compared by the ROC curve. SS SP version 25, X-Tile version 3.6.1, and R version 4.0.2 were used for data analysis. The statistical significance of the p value was set at 0.05 (double-sided).

RESULTS

Patient Characteristics

A total of 91 high-grade glioma patients (36 cases of grade III and 55 cases of grade IV) were enrolled. The median age was 50 years (range 18–79 years). Table 1 showed the characteristics of grade III and grade IV glioma patients and their correlation with preoperative PNI. In patients with grade III and grade IV glioma, the best cutoff values of preoperative PNI were 47 and 44, respectively.

Survival Analysis

The median follow-up time for all patients was 21 months (95% CI: 23.4–31.4 months). The median OS for grade III glioma was 31 months (95% CI: 28.9–41.6 months), and the median OS for grade IV glioma was 17 months (95% CI: 17.5–27.1 months). Among patients with grade III glioma, the median OS of patients...
in the preoperative low PNI (≤47) group and high PNI (>47) group was 22 and 37 months, respectively. In grade IV glioma, the median OS for the preoperative lower PNI (≤44) group and higher PNI (>44) group was 14 and 17.5 months.

The Kaplan–Meier survival curve and log-rank test were used to analyze the prognosis of patients in different PNI states. It was found that in grade III glioma, the OS of patients with preoperative high PNI status was significantly longer than that of preoperative low PNI status (Figure 1A, p = 0.023). However, the Kaplan–Meier curve intersected, suggesting that in grade III gliomas, there may be confounding factors that make patients with high PNI have longer OS, so we conducted a multivariate analysis. Grade IV glioma patients with higher preoperative PNI also showed a similar trend of obtain better prognosis (Figure 1B, p = 0.138).

Cox regression analysis showed that in grade IV glioma, preoperative PNI level, extent of resection, and MGMT methylation status were significantly correlated with OS (Table 2). Since primary and secondary grade IV gliomas were usually distinguished according to the wild type and mutant type of IDH (14), and the predictive value of preoperative PNI in patients with different types of grade IV gliomas may be different, we performed subgroup analysis on IDH wild-type grade IV glioma patients. The results showed that patients with higher preoperative PNI had a tendency to obtain OS benefits (HR = 0.476, p = 0.126, Table 3). We did not further analyze the role of PNI in secondary grade IV gliomas due to the small number of IDH mutated grade IV gliomas patients included (n = 9). In grade III glioma, age, histological type, extent of resection, MGMT methylation status, and Ki-67 level were independent

### Table 1 | Baseline patient characteristics stratified by preoperative PNI in grade III glioma and grade IV glioma.

| Variables | Grade III glioma | | Grade IV glioma | |
|-----------|-----------------|-----------------|-----------------|-----------------|
|           | Total (n = 36)  | PNI ≤47 (n = 9, 25%) | PNI >47 (n = 27, 75%) | p  | Total (n = 55)  | PNI ≤44 (n = 7, 12.7%) | PNI >44 (n = 48, 87.3%) | p  |
| Age | n/mean ± SD | n/mean ± SD | n/mean ± SD | p | n/mean ± SD | n/mean ± SD | n/mean ± SD | p |
|   | 48.4 ± 10.30 | 53.2 ± 9.75 | 46.7 ± 10.95 | 0.103 | 51.1 ± 14.26 | 51.7 ± 16.59 | 51.0 ± 14.08 | 0.906 |
| Sex | Female | 14 ± 3.89 | 3 ± 1.00 | 11 ± 1.00 | 1.000 | 29 ± 5 ± 25.7 | 4 ± 1.00 | 25.0 ± 1.00 | 1.000 |
|   | Male | 22 ± 61.1 | 3 ± 16.0 | 22 ± 16.0 | 1.000 | 26 ± 61.1 | 3 ± 16.0 | 23 ± 16.0 | 1.000 |
| Histology | AA | 21 ± 58.3 | 5 ± 16 | 1.000 | 0.681 | NA | NA | NA | NA |
|   | AO | 13 ± 36.1 | 3 ± 10 | NA | NA | NA | NA | NA | NA |
|   | GBM | NA | NA | NA | NA | NA | NA | NA | NA |
|   | NOS | 2 ± 5.6 | 1 ± 1 | NA | NA | NA | NA | NA | NA |
| Main location | Frontal | 25 ± 69.4 | 5 ± 20 | 1.000 | 0.531 | 32 ± 58.2 | 5 ± 27 | 0.686 | 0.513 |
|   | Parietal | 4 ± 11.1 | 1 ± 3 | 1.000 | 1.000 | 18 ± 32.7 | 2 ± 16 | 1.000 | 1.000 |
|   | Occipital | 2 ± 5.6 | 1 ± 1 | 1.000 | 0.443 | 9 ± 16.4 | 0 ± 9 | 0.480 | 0.480 |
|   | Temporal | 9 ± 25.0 | 3 ± 6 | 1.000 | 0.824 | 12 ± 21.8 | 2 ± 10 | 1.000 | 1.000 |
|   | Insular | 1 ± 2.8 | 1 ± 0 | 1.000 | 0.250 | 2 ± 3.6 | 0 ± 2 | 1.000 | 1.000 |
| No. of glioma | Single | 36 ± 100 | 9 ± 27 | NA | NA | 49 ± 89.1 | 6 ± 43 | 0.577 | 0.577 |
|   | Multiple | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.00 | 6 ± 10.9 | 1 ± 5 | 0.513 | 0.513 |
| Extent of resection | PRI | 2 ± 5.6 | 0 ± 2 | 1.000 | 0.513 | 0 ± 0 | 0 ± 0 | 0.513 | 0.513 |
|   | STR | 3 ± 8.3 | 1 ± 2 | 1.000 | 0.513 | 6 ± 10.9 | 0 ± 6 | 0.513 | 0.513 |
|   | NTR | 6 ± 16.7 | 1 ± 5 | 1.000 | 0.513 | 8 ± 14.5 | 0 ± 8 | 0.513 | 0.513 |
|   | GTR | 25 ± 69.4 | 7 ± 18 | 1.000 | 0.513 | 41 ± 74.5 | 7 ± 34 | 0.513 | 0.513 |
| IDH mutation | No | 2 ± 5.6 | 0 ± 2 | 1.000 | 0.513 | 46 ± 83.6 | 6 ± 40 | 1.000 | 1.000 |
|   | Yes | 34 ± 94.4 | 9 ± 25 | 1.000 | 0.513 | 9 ± 16.4 | 1 ± 8 | 0.513 | 0.513 |
| MGMT methylation | No | 14 ± 38.9 | 5 ± 9 | 1.000 | 0.513 | 34 ± 61.8 | 4 ± 30 | 1.000 | 1.000 |
|   | Yes | 22 ± 61.1 | 4 ± 18 | 1.000 | 0.513 | 21 ± 38.2 | 3 ± 18 | 1.000 | 1.000 |
| 1p19q deletion | No | 23 ± 63.9 | 6 ± 17 | 1.000 | 0.513 | 0 ± 0 | 0 ± 0 | 0.513 | 0.513 |
|   | Yes | 13 ± 36.1 | 3 ± 10 | 1.000 | 0.513 | 0 ± 0 | 0 ± 0 | 0.513 | 0.513 |
| Ki-67 | 16.3 ± 22.2 | 14.3 ± 0.311 | 27.6 ± 35.0 | 26.5 ± 0.145 | 1.000 | 0.145 | 1.000 | 1.000 |
|   | 14.44 ± 21.38 | 11.12 ± 14.43 | 18.03 ± 13.72 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |

AA, anaplastic astrocytomas; AO, anaplastic oligodendrogliomas; GBM, glioblastoma; GTR, gross total resection; n, number; NA, not applicable; No., number; NOS, not otherwise specified; NTR, near total resection; PNI, prognostic nutritional index; PRI, partial resection; SD, Std. deviation; STR, subtotal resection.
prognostic factors that affect OS in patients (Table 4), and patients with higher preoperative PNI showed a better prognosis only in the univariate analysis (HR = 0.301, p = 0.032).

When assessing the prognostic ability of PNI in grade III and IV gliomas through the ROC curve, we found that the AUC was not high (0.65 and 0.50, respectively, Figure 2), which indicated that PNI alone had a limited effect of predicting OS in patients with high-grade glioma.

The Establishment of a Nomogram

Important factors associated with the prognosis of high-grade gliomas included age, extent of resection, number of gliomas, and MGMT methylation status. Since our study showed that preoperative PNI level was an independent prognostic factor in grade IV glioma patients, however, in grade III glioma, a significant correlation between PNI and OS was only shown in univariate analysis, and the number of patients with grade III glioma included was relatively small. Therefore, we only drew a nomogram in grade IV gliomas covering preoperative PNI, age, extent of resection, number of gliomas, and MGMT methylation status (Figure 3) and evaluated the predictive effect of the nomogram. The C-index of the nomogram was 0.771 (95% CI: 0.708–0.834). The calibration curves for the 1-, 2-, and 3-year survival of the patients showed that when predicting the 2-year survival rate, the agreement between the prediction and the observation results was the best (Figures 4A–C), indicating that the repeatability of the nomogram was reliable. ROC analysis showed that the AUC of the nomogram covering the

TABLE 2 | Univariate and multivariate Cox regression analyses for overall survival in grade IV glioma patients.

| Variable                  | Univariate Cox regression | Multivariate Cox regression |
|---------------------------|----------------------------|-----------------------------|
|                          | p value  | HR (95% CI)    | p value  | HR (95% CI)    |
| Age                       | 0.105    | 1.019 (0.996 -1.042) | 0.382 | 1.010 (0.988 -1.032) |
| Sex                       |          |                 | 0.501 |                 |
| Female                    | ref      | 1.000 (0.885 -1.125) | ref      | 1.000 (0.885 -1.125) |
| Male                      | 0.537    | 1.222 (0.646 -2.313) | 0.537    | 1.222 (0.646 -2.313) |
| No. of glioma             |          |                 | 0.016 |                 |
| Single                    | ref      | 1.000 (0.885 -1.125) | 0.016 | 3.321 (1.247 -8.847) |
| Multiple                  | 0.016    | 3.321 (1.247 -8.847) | 0.016    | 3.321 (1.247 -8.847) |
| Extent of resection       |          |                 | 0.001 |                 |
| STR+PR                    | ref      | 1.000 (0.885 -1.125) | 0.001 | 0.200 (0.078 -0.514) |
| GTR+NTR                   | 0.001    | 0.200 (0.078 -0.514) | 0.001    | 0.200 (0.078 -0.514) |
| IDH mutation              |          |                 | 0.004 |                 |
| No                        | ref      | 1.000 (0.885 -1.125) | 0.004 | 0.171 (0.051 -0.574) |
| Yes                       | 0.004    | 0.171 (0.051 -0.574) | 0.004    | 0.171 (0.051 -0.574) |
| MGMT methylation          |          |                 | 0.004 |                 |
| No                        | ref      | 1.000 (0.885 -1.125) | 0.004 | 0.293 (0.14 -0.615) |
| Yes                       | 0.004    | 0.293 (0.14 -0.615) | 0.004    | 0.293 (0.14 -0.615) |
| Ki-67                     |          |                 | 0.580 |                 |
| No                        | ref      | 1.000 (0.885 -1.125) | 0.580 | 1.006 (0.988 -1.028) |
| Yes                       | 0.580    | 1.006 (0.988 -1.028) | 0.580 | 1.006 (0.988 -1.028) |
| PNI before surgery        |          |                 | 0.508 |                 |
| No                        | ref      | 1.000 (0.885 -1.125) | 0.508 | 1.000 (0.885 -1.125) |
| Yes                       | 0.508    | 1.000 (0.885 -1.125) | 0.508 | 1.000 (0.885 -1.125) |
| PNI                        |          |                 | 0.155 |                 |
| ≤44                       | ref      | 1.000 (0.885 -1.125) | 0.155 | 0.548 (0.239 -1.255) |
| >44                       | 0.155    | 0.548 (0.239 -1.255) | 0.155    | 0.548 (0.239 -1.255) |

CI, confidence interval; GTR, gross total resection; HR, hazard ratio; No., number; NTR, near total resection; PNI, prognostic nutritional index; PR, partial resection; ref, reference; STR, subtotal resection.

*Statistically significant (p < 0.05).
TABLE 3 | Univariate and multivariate Cox regression analyses for overall survival in the IDH wide-type IV glioma subgroup.

| Variable               | Univariate Cox regression | Multivariate Cox regression |
|------------------------|---------------------------|-----------------------------|
|                        | p value | HR (95% CI) | p value | HR (95% CI) |
| Age                    | 0.513     | 1.007 (0.985 -1.030) | 0.834     | 1.002 (0.980 -1.025) |
| Sex                    | Female ref | Male 0.767 | 1.106 (0.568 -2.152) | ref |
| No. of glioma          | Single ref | Multiple 0.058 | 2.568 (0.967 -6.822) | ref |
| Extent of resection    | STR+PR ref | GTR+NTR 0.004* | 0.254 (0.099 -0.652) | ref |
| MGMT methylation       | No ref | Yes 0.087 | 0.504 (0.230 -1.105) | ref |
| Ki-67                  | No ref | Yes 0.012* | 3.684 (1.338 -10.143) | ref |
| Epilepsy before surgery| No ref | Yes 0.012* | 3.684 (1.338 -10.143) | ref |
| PNI                    | ≤44 ref | >44 0.369 | 0.666 (0.274 -1.617) | ref |

CI, confidence interval; GTR, gross total resection; HR, hazard ratio; No., number; NTR, near total resection; PNI, prognostic nutritional index; PR, partial resection; ref, reference; STR, subtotal resection.

*Statistically significant (p < 0.05).

TABLE 4 | Univariate and multivariate Cox regression analyses for overall survival in grade III glioma patients.

| Variable               | Univariate Cox regression | Multivariate Cox regression |
|------------------------|---------------------------|-----------------------------|
|                        | p value | HR (95% CI) | p value | HR (95% CI) |
| Age                    | 0.008* | 1.078 (1.020 -1.139) | 0.002* | 1.137 (1.047 -1.234) |
| Sex                    | Female ref | Male 0.914 | 1.062 (0.355 -3.181) | ref |
| Histology              | AA ref | AO 0.525 | 0.682 (0.210 -2.220) | ref |
|                       | NOS ref | STR+PR 0.875 | 1.183 (0.147 -9.483) | ref |
|                       | GTR+NTR ref | No 0.004* | 0.195 (0.063 -0.599) | ref |
| IDH-mutation           | No ref | Yes 0.848 | 0.819 (0.106 -6.311) | ref |
|                       | NOS ref | 0.187 | 0.487 (0.167 -1.418) | ref |
| 1p19q deletion         | No ref | Yes 0.503 | 0.672 (0.210 -2.149) | ref |
|                       | NOS ref | 0.018* | 1.043 (1.007 -1.080) | ref |
| Ki-67                  | No ref | Yes 0.081 | 0.318 (0.088 -1.151) | ref |
|                       | <47 ref | >47 0.032* | 0.301 (0.100 -0.904) | ref |

CI, confidence interval; GTR, gross total resection; HR, hazard ratio; NOS, not otherwise specified; NTR, near total resection; PNI, prognostic nutritional index; PR, partial resection; ref, reference; STR, subtotal resection.

*Statistically significant (p < 0.05).
This study mainly explored the predictive value of preoperative PNI in patients with operable high-grade glioma. We only included patients with high-grade glioma who received standardized postoperative adjuvant radiotherapy and chemotherapy. After excluding the influence of treatment factors, it could better reflect the predictive ability of preoperative PNI. The IDH mutation frequency (94% and 16%, respectively) and MGMT methylation frequency (61%...
and 38%, respectively) of grade III and grade IV glioma reported in our study were consistent with the frequency reported in the past (26, 27). Some factors that affect the prognosis of patients with high-grade glioma, such as age, histological type, single or multiple gliomas, extent of resection, MGMT methylation status, and Ki-67 level, were verified in our results (27–32). However, the OS of patients with different IDH statuses did not show significant statistical differences. It may be related to the small number of IDH wild-type grade III glioma patients and IDH mutant grade IV glioma patients we included. Regarding PNI, consistent with most studies, we found that preoperative PNI showed a predictive value (13). Our study found that in grade III and grade IV gliomas, the median OS of patients with higher preoperative PNI was longer than that of patients with lower PNI. Preoperative PNI was an independent prognostic factor for grade IV glioma. However, in univariate analysis, patients with higher preoperative PNI only had trends to get better OS. This may be because OS was affected by other factors in addition to preoperative PNI. When a multivariate analysis was performed, the significance of preoperative PNI becomes apparent.
Furthermore, through ROC analysis, the nomogram covering PNI also showed a better prognostic value compared with the prediction model without PNI. In the IDH wild-type grade IV glioma subgroup, higher PNI only showed a trend for better OS. This may be due to the small number of IDH wild-type IV glioma patients included (n = 46). In this study, PNI did not show a good prognostic effect in grade III gliomas. Although our study showed that PNI in grade III gliomas was statistically significant in univariate Cox regression and Kaplan–Meier analysis, the intersecting Kaplan–Meier curves suggested that there might be confounding factors. Multivariate Cox analysis showed that the PNI was not an independent prognostic factor for grade III gliomas. This may be due to the strong heterogeneity of grade III gliomas, and a single indicator may not be used as a reliable independent prognostic factor. Moreover, the number of grade III gliomas patients we included was small (n = 36), which may be insufficient to support the inclusion of more indicators for multivariate analysis. In the future, we will follow more patients to evaluate the predictive value of PNI in grade III gliomas. In addition, we included 2 IDH wild-type grade III glioma patients. Some IDH wild-type grade III glioma patients may be classified as grade IV glioma with the development of molecular pathology (33). In the future, we would include more patients and evaluate the prognostic value of PNI in different subtypes of high-grade gliomas. Although, through the ROC curve, we found that in high-grade glioma, the predictive effect of PNI alone was limited, the nomogram based on PNI showed good predictive performance. The AUC of the nomogram covering PNI was higher than that of the prediction model without PNI. This showed that the nomogram covering preoperative PNI was better than traditional biomarkers. The molecular pathological diagnosis of patients may change with the advancement of molecular detection in the future. We will continue to include more patients and further optimize the nomogram to more accurately predict the OS of patients with high-grade glioma.

As a cheap and convenient indicator, PNI may affect the prognosis of patients with malignant tumors in many ways. Many studies found that the level of albumin was related to the nutritional status of patients and the immune system (34). Lower serum albumin levels indicated an increased nutritional risk for malignant tumor patients. In addition, lower albumin levels could also interfere with the body’s immune response and reduce antitumor effects (34, 35). Lymphocytes were an important cell group for body immunity and an important factor for regulating immunity. Lymphocytes could limit tumor growth and metastasis through cytotoxicity and improve patient prognosis (36, 37). Therefore, high levels of PNI may often be associated with better prognosis in patients with malignant tumors. However, in high-grade gliomas, this conclusion was not always valid, and more clinical data were still needed to explore the prognostic value of PNI in high-grade gliomas. Due to the special microenvironment of glioma, its immune response was different from other solid tumors. First, most immune cells could not pass the blood–brain barrier smoothly, and high-grade gliomas were relatively “cold” tumors (38). Secondly, the ratio of CD4+ T cells, CD8+ T cells, regulatory T cells (Treg), and other types of T lymphocytes in the glioma microenvironment was different. Studies showed that the number of CD4+ T cells, CD8+ T cells, and Treg cells could affect the tumor immune response in gliomas (39–41). In addition, gliomas could also be divided into different subtypes according to the Tumor Genomics Atlas Project (TCGA), and the prognosis of different subtypes may be different (42, 43). These may be the reasons why the findings found in other malignant tumors did not necessarily exist in high-grade gliomas.

There was no doubt that this study had certain limitations (1). As a single-center, retrospective study, the number of patients included in this study was limited and the follow-up time was insufficient. Moreover, the number of people in the high-PNI and low-PNI groups was uneven. We will continue to follow up more patients to obtain more accurate results (2). The biomarker status of the tumor may affect the prognosis of patients with high-grade glioma. We would continue to follow up and include more patients with more accurate tumor molecular classification to verify our findings and optimize the nomogram (3). Patients with high-grade glioma may receive different treatments after surgery, such as tumor-treating fields and bevacizumab, and the duration of treatment may also be different. All of these may lead to bias in research results. More prospective clinical trials were needed to evaluate the prognostic value of PNI in patients with high-grade glioma (4). Although the OS predicted by the nomogram was in good agreement with the observed OS, the general applicability of the findings still needed to be confirmed by external verification.

CONCLUSIONS

Preoperative PNI level was an independent prognostic factor for patients with grade IV glioma. The nomogram covering PNI could predict the prognosis of patients with grade IV glioma more accurately than traditional markers. The value of PNI in grade III glioma needs to be further evaluated. More large-scale prospective clinical trials are needed to evaluate the prognostic value of preoperative PNI in high-grade gliomas.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for
participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

(I) Conception and design: all authors. (II) Administrative support: none. (III) Provision of study materials or patients: QH, QR. (IV) Collection and assembly of data: QH, WZ. (V) Data analysis and interpretation: QH, QR. (VI) Manuscript writing: all authors. (VII) Final approval of manuscript: all authors. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Ostrom QT, CiofﬁG, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21 (Suppl 5):v1–100. doi: 10.1093/neuono/vnz150
2. Qian BZ. Inflammation Fires Up Cancer Metastasis. Semin Cancer Biol (2017) 47:170–6. doi: 10.1016/j.semcancer.2017.08.006
3. Hung RJ, Ulrich CM, Goode EL, Bhanez Y, Muir K, Chan AT, et al. Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J Natl Cancer Inst (2015) 107(11). doi: 10.1093/jncli/djv246
4. Barahona Ponce C, Scherer D, Brinster R, Boekstegers F, Marcelin K, Garaë-Calderon V, et al. Gallstones, Body Mass Index, C-Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data. Hepatology (2021) 73(5):1783–96. doi: 10.1002/hep.31537
5. Sasaki M, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M, et al. The Geriatric Nutritional Risk Index Predicts Postoperative Complications and Prognosis in Elderly Patients With Colorectal Cancer After Curative Surgery. Sci Rep (2020) 10(1):10744. doi: 10.1038/s41598-020-67285-y
6. Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment Prognostic Nutritional Index as a Prognostic Factor in Lung Cancer: Review and Meta-Analysis. Clin Chim Acta (2018) 486:303–10. doi: 10.1016/j.cca.2018.08.030
7. Hao J, Chen C, Wan F, Zyu J, Jin H, Zhou J, et al. Prognostic Value of Pretreatment Prognostic Nutritional Index in Esophageal Cancer: A Systematic Review and Meta-Analysis. Front Oncol (2020) 10:797. doi: 10.3389/fonc.2020.00797
8. Hua X, Long ZQ, Huang X, Deng JP, He ZY, Guo L, et al. The Value of Prognostic Nutritional Index (PNI) in Predicting Survival and Guiding Radiotherapy of Patients With T1-2n1 Breast Cancer. Front Oncol (2019) 9:1562. doi: 10.3389/fonc.2019.01562
9. Gao QL, Shi JG, Huang YD. Prognostic Signiﬁcance of Pretreatment Prognostic Nutritional Index (PNI) in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis. Nutr Cancer (2020) 73(9):1657–67. doi: 10.1080/01635581.2020.1810715
10. Sun G, Li Y, Peng Y, Lu D, Zhang F, Cui X, et al. Impact of the Pretreatment Prognostic Nutritional Index on Postoperative and Survival Outcomes in Colorectal Cancer Patients Who Underwent Primary Tumor Resection: A Systematic Review and Meta-Analysis. Int J Colorectal Dis (2019) 34(4):681–9. doi: 10.1007/s00384-019-02341-1
11. Oh SE, Choi MG, Seo JM, An JY, Lee JH, Sohn TS, et al. Prognostic Signiﬁcance of Perioperative Nutritional Parameters in Patients With Gastric Cancer. Clin Nutr (2019) 38(2):870–6. doi: 10.1016/j.clnu.2018.02.015
12. Lv X, Zhang Z, Yuan W. Pretreatment Prognostic Nutritional Index (PNI) as a Prognostic Factor in Patients With Biliary Tract Cancer: A Meta-Analysis. Nutr Cancer (2020) 73(10):1872–81. doi: 10.1080/01635581.2020.1817955
13. Liu M, Wang L. Prognostic Signiﬁcance of Preoperative Serum Albumin, Albumin-to-Globulin Ratio, and Prognostic Nutritional Index for Patients With Glioma: A Meta-Analysis. Med (Baltimore) (2020) 99(27):e20927. doi: 10.1097/md.0000000000020927

ACKNOWLEDGMENTS

Thanks are given for the data support provided by the First Affiliated Hospital of Chongqing Medical University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.724769/full#supplementary-material
Glioblastoma: A Retrospective Cohort Study. *J Neurooncol* (2020) 146(1):55–62. doi: 10.1007/s11060-019-03334-5

29. Neter-Garcia E, Lorente Estellés D, Alvarez-Torres MDM, Juan-Albarracin J, Chelebian E, Rovira A, et al. MGMT Methylation by Benefit Overall Survival in Patients With Moderately Vascularized Glioblastomas. *Eur Radiol* (2021) 31(3):1738–47. doi: 10.1007/s00330-020-07297-4

30. Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, et al. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. *JAMA Oncol* (2017) 3(6):784–92. doi: 10.1001/jamaoncol.2016.6020

31. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the Molecular Genetics of Gliomas – Implications for Classification and Therapy. *Nat Rev Clin Oncol* (2017) 14(7):434–52. doi: 10.1038/nrclinonc.2016.204

32. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* (2020) 18(11):1537–70. doi: 10.6004/jnccn.2020.0052

33. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood. *Nat Rev Clin Oncol* (2021) 18(3):170–86. doi: 10.1038/s41571-020-00447-2

34. Moujaes E, Fakhoury M, Assi T, Elias H, El Karak F, Ghosn M, et al. The Therapeutic Use of Human Albumin in Cancer Patients' Management. *Crit Rev Oncol Hematol* (2017) 120:203–9. doi: 10.1016/j.critrevonc.2017.11.008

35. Almasaudi AS, Dolan RD, Edwards CA, McMillan DC. Hypoalbuminemia Reflects Nutritional Risk, Body Composition and Systemic Inflammation and Is Independently Associated With Survival in Patients With Colorectal Cancer. *Cancers (Basel)* (2020) 12(7). doi: 10.3390/cancers12071986

36. Chapuis AG, Roberts JM, Thompson JA, Margolin KA, Bhatia S, Lee SM, et al. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. *J Clin Oncol* (2016) 34(31):3787–95. doi: 10.1200/jco.2015.65.5142

37. Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. *Cell Res* (2017) 27(8):1034–45. doi: 10.1038/cr.2017.90

38. Lim M, Xia Y, Bettegowda C, Weller M. Current State of Immunotherapy for Glioblastoma. *Nat Rev Clin Oncol* (2018) 15(7):422–42. doi: 10.1038/s41571-018-0003-5

39. Zhang W, Wu S, Guo K, Hu Z, Peng J, Li J. Correlation and Clinical Significance of LC3, CD68+ Microglia, CD4+ T Lymphocytes, and CD8+ T Lymphocytes in Gliomas. *Clin Neurol Neurosurg* (2018) 168:167–74. doi: 10.1016/j.clineuro.2018.02.044

40. Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. *Front Genet* (2020) 11:363. doi: 10.3389/fgen.2020.00363

41. Long Y, Tao H, Karachi A, Grippin AJ, Jin L, Chang YE, et al. Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. *Cancer Res* (2020) 80(3):499–509. doi: 10.1158/0008-5472.Can-19-1577

42. Hao Z, Guo D. EGFR Mutation: Novel Prognostic Factor Associated With Immune Infiltration in Lower-Grade Glioma: an Exploratory Study. *BMC Cancer* (2019) 19(1):1184. doi: 10.1186/s12885-019-6384-8

43. Pan YB, Zhang CH, Wang SQ, Ai PH, Chen K, Zhu L, et al. Transforming Growth Factor Beta Induced (TGFBI) Is a Potential Signature Gene for Mesenchymal Subtype High-Grade Glioma. *J Neurooncol* (2018) 137 (2):395–407. doi: 10.1007/s11060-017-2729-9

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 He, Zhao and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.